|
|
 |
 |
|
|
|
|
|
|
|
|
| |
|
|
|
|

Photo courtesy of Discovery Communications |
|
|
|
|
 |
 |
 |
|
Robert
Ausman, MD
Robert Ausman, MD is the retired President
for Advanced Development at Baxter Health Care and Clinical Professor
of Surgery at the Medical College of Wisconsin. Prior to this,
he served as Vice President of clinical research at Baxter. As
a leading innovator of medical devices and products, he has developed
and advanced such devices as TPN formulations, infusion pumps,
and other medical products. He is a practicing oncologist and
has had numerous articles and books published throughout his professional
career. Dr. Ausman received his M.D. from Marquette University
and his Ph. D. from the University of Minnesota. |
|
| |
|
|
|

|
|
Andreas Barner, Ph.D, M.D.
Dr. Andreas Barner is Vice Chairman and Member
of the Board of Managing Directors of Boehringer Ingelheim GmbH,
Germany, responsible for the Corporate Board Division Pharma-Research,
Development and Medicine. Prior to this he was Corporate Medical
Director responsible for global clinical research, drug regulatory
affairs, information & biometry, and drug safety. Prior to
this he was Head of the Corporate Medical Department. Dr. Barner
joined Boehringer Ingelheim in January 1992 from Ciba-Geigy AG
(Novartis) in Basle, Switzerland where he was Head of the Development
Indication Area for Inflammatory, Bone and Allergy Diseases within
the Research and Development Department. He began his professional
career at Ciba-Geigy in the Central Function of Research and the
Medical Department. He obtained his medical degree and doctoral
degree in Medicine from the University of Freiburg and his PhD
in Mathematics from the Swiss Federal Institute of Technology.
Dr. Barner is the Chairman of the German Association of Research
based Pharmaceutical Companies (VFA) and currently serves as Deputy
Chair Person of the NGFN Steering Committee (National Genome Research
Network), Member of the EFPIA R&D Directors’ Group,
Member of the Advisory Board to the University of Mainz, and Member
of the Board of Trustees of the German Chemical Industry Fund.
|
|
| |
|
|
|
|
|
Gerard
M. Edelman, M.D.
Dr. Gerard M. Edelman is the Chairman of NGN
Capital’s Advisory Board. Nobel Laureate, Chairman, Neurobiology
Scripps Research, Immunologist; born in New York City. He practiced
medicine at both Massachusetts General Hospital (1957-60), and
the hospital of Rockefeller University. He joined the faculty
of Rockefeller (1960-81) and became director of their Neurosciences
Institute (1981). He shared the 1972 Nobel Prize in physiology
for his investigations of the structure of the primary human antibody,
immunoglobulin G. He then focused his research on cellular immune
responses and intercellular communication in the immune system
and the brain. Dr. Edelman is a member of the National Academy
of Sciences, the American Academy of Arts and Sciences, the American
Society of Biological Chemists and the American Association of
Immunologists, as well as a number of other scientific societies.
|
|
| |
|
|
|
|
|
|
Gerard
M. Moufflet
Gerard M. Moufflet is CEO of KIKA Medical International,
an NGN portfolio company, and CEO and Founder of Acceleration
International, a private equity firm investing in the healthcare
industry. He has been active in the healthcare field worldwide
for over 30 years. From 1989 to 2001 Mr. Moufflet was a Managing
Director at Advent International, heading the healthcare team
of one of the world's leading private equity investment firms
with over $6 billion funds under management. From 1972 to 1989
Mr. Moufflet served as Corporate Vice President of Baxter and
Vice President of Baxter World Trade. Mr. Moufflet serves on the
board of public U.S. companies American Dental Partners, Curative
Health Services, Serologicals Inc. and several private companies
including Thommen Medical and Medical Simulation. Mr. Moufflet
is also the Chairman of the Board of Fellows of the Harvard Dental
School of medicine. Mr. Moufflet is a graduate of the EDHEC Business
School in France, holds an MBA (1969) from the University of Pittsburgh.
He is a Harvard Business School AMP (1987). He has been honored
by the President of France as a "Chevalier de l'Ordre du
Merite National".
|
|
| |
|
|
|

Photo courtesy
of Discovery Communications |
|
Dr.
Mehmet C. Oz
Mehmet C. Oz, MD is Vice-Chair
and Professor of Surgery at Columbia University. He directs the
Cardiovascular Institute and Complementary Medicine Program at
New York Presbyterian Hospital. His research interests include
heart replacement surgery, minimally invasive cardiac surgery,
complementary medicine and health care policy. He has authored
over 400 original publications, book chapters, and medical books
and has received several patents. He performs over 350 heart operations
annually. Dr Oz authored the award winning “Healing from
the Heart” (Dutton Penguin Putnam 1998) as well as numerous
pieces in Newsweek, Oprah Magazine, and the New England Journal
of Medicine. He has a bi-monthly column in Esquire magazine. He
also wrote “You: The Owner’s Manual,” (Harper
Collins, 2005),which became a New York Times Bestseller. In addition
to belonging to every major professional society for heart surgeons,
Dr Oz was elected as a Global Leader of Tomorrow by the World
Economic Forum, won the prestigious American Association for Thoracic
Surgery Gross Research Scholarship, and has received an honorary
doctorate from Istanbul University, He was voted "The Best
and Brightest" by Esquire Magazine and was elected one of
the Doctors of the Year by Hippocrates magazine and Healers of
the Millennium by Healthy Living magazine. He is annually elected
as one of the best physicians in the U.S. by the Castle Connolly
Guide as well as other major ranking groups. Dr. Oz received his
undergraduate degree from Harvard University (1982) and obtained
a joint MD and MBA (1986) from the University of Pennsylvania
School of Medicine and Wharton Business School. He was awarded
the Captain’s Athletic Award for leadership in college and
was Class President followed by President of the Student Body
during medical school.
|
|
| |
|
|
|
|
|
Peter
Sjöstrand, M.D.
Dr. Peter Sjöstrand is currently Chairman
of Gambro AB and Chairman of Innate Pharmaceuticals AB in Sweden.
He had been Executive Vice President, CFO and temporary CEO of
The Astra Group, serving as Member of the Executive Committee
and Board of Directors in a career of almost 20 years at Astra
(1975-1993). He had regional responsibility for the Americas including
the joint venture with Merck & Co and its launch of Prilosec®,
which at the time was the largest selling pharmaceutical product
blockbuster in U.S. history. Prior to this, Dr. Sjöstrand
was Consultant at the Maynard Company since 1970. Dr. Sjöstrand
obtained his medical doctor degree at the Karolinska Institute
in Stockholm and holds a B.S. in Economics from the Stockholm
School of Economics. Dr. Sjöstrand currently serves on the
board of the U.S. Carlyle Group’s European advisory Board,
as Chairman of the Board of Meda AB, Microdrug AG, Oscar Hirsch
Memory Foundation, Jacob Wallenberg’s & Madleine Sager’s
Foundation, as Treasurer of the Swedish Heart & Lung Foundation,
and as Director of Active Biotech AB. He previously has been a
Director of Pharma Vision AG, Montana Switzerland, Trygg-Hansa,
Aga AB, and Tularik. |
|
| |
|
|
|
 |
Top
of Page
Print Version |
 |
 |